(NASDAQ: PRAX) Praxis Precision Medicines's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Praxis Precision Medicines's revenue in 2026 is $0.On average, 21 Wall Street analysts forecast PRAX's revenue for 2026 to be $72,871,169, with the lowest PRAX revenue forecast at $0, and the highest PRAX revenue forecast at $355,896,087. On average, 20 Wall Street analysts forecast PRAX's revenue for 2027 to be $9,712,247,026, with the lowest PRAX revenue forecast at $3,836,764,751, and the highest PRAX revenue forecast at $19,738,593,916.
In 2028, PRAX is forecast to generate $31,856,706,308 in revenue, with the lowest revenue forecast at $14,135,889,924 and the highest revenue forecast at $58,687,814,776.